A number of stock research firms have changed their ratings and price targets for Gilead Sciences (NASDAQ: GILD) during the last seven days:

  • Gilead Sciences had its “market perform” rating reaffirmed by analysts at Sanford C. Bernstein. They now have a $63.00 price target on the stock.
  • Gilead Sciences had its “outperform” rating reaffirmed by analysts at RBC Capital. They now have a $80.00 price target on the stock.
  • Gilead Sciences had its “neutral” rating reaffirmed by analysts at Lazard Capital.
  • Gilead Sciences was upgraded by analysts at Bernstein from a “market perform” rating to an “outperform” rating. They now have a $80.00 price target on the stock, up previously from $63.00.
  • Gilead Sciences had its “outperform” rating reaffirmed by analysts at Cowen.
  • Gilead Sciences had its price target raised by analysts at UBS AG from $65.00 to $80.00. They now have a “buy” rating on the stock.
  • Gilead Sciences had its “outperform” rating reaffirmed by analysts at Wells Fargo & Co..

Shares of Gilead Sciences, Inc. opened at 69.995 on Thursday. Gilead Sciences, Inc. has a 52 week low of $34.45 and a 52 week high of $70.39. The company has a market cap of $52.956 billion and a P/E ratio of 21.20.

Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.